Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Par Launches Generic Zofran ODT Following FDA Clearance

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency also clears Dr. Reddy’s immediate-release ondansetron formulation which the Indian firm said it will launch shortly.

You may also be interested in...



Dr. Reddy’s Tops Billion Dollar Mark In First Nine Months Of Fiscal 2007

Indian generic drug maker achieved the milestone on acquisitions supported by a “strong and profitable” growth engine.

Dr. Reddy’s Tops Billion Dollar Mark In First Nine Months Of Fiscal 2007

Indian generic drug maker achieved the milestone on acquisitions supported by a “strong and profitable” growth engine.

Dr. Reddy's Tops Billion Dollar Mark In First Nine Months Of Fiscal 2007

Dr. Reddy's Laboratories reported revenues exceeding $1 billion for the first time during the first nine months of fiscal 2007 (ended Dec. 31)

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel